Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 10/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15125586 | 0.95 | EPHX2 (0.55) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL3672272 | 0.84 | CYP2C9 (0.48) | MEN1KMT2ACYP2C19CA1CA2 | |
| SCHEMBL15125608 | 0.84 | EPHX2 (0.44) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL15125582 | 0.84 | EPHX2 (0.44) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL11774 | 0.83 | ANPEP (0.56) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL11960443 | 0.83 | EPHX2 (0.55) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL10697579 | 0.83 | NR1H4 (0.64) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL21556997 | 0.83 | SHBG (0.49) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL11960431 | 0.82 | HDAC3 (0.56) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL4020664 | 0.81 | IDO1 (0.56) | EPHX2HDAC3HDAC8HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047320-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-6787569-B1 | INHIBITORS OF NEUROTRANSMITTER (E.G., GLUTAMATE) RELEASE FROM ISCHEMIC NEURONAL CELLS; N,N-DISUBSTITUTED GUANIDINES; NEUROLOGICAL CONDITIONS SUCH AS EPILEPSY, NEURODEGENERATIVE CONDITIONS AND/OR NERVE CELL DEATH FROM STROKE OR HEART ATTACK | CAMBRIDGE NEUROSCIENCE, INC. | 2004-09-07 | — | — | US | disclosed |
| US-6288123-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCES, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6174924-B1 | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | EPHX2 3041/4885NR1H4 3843/4885HDAC3 2555/4885 |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | GAP43, NLN, HTT | EPHX2 2740/4885NR1H4 3670/4885HDAC3 1591/4885 |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | EPHX2 3007/4885NR1H4 3803/4885HDAC3 2558/4885 |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | EPHX2 3041/4885NR1H4 3843/4885HDAC3 2555/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | EPHX2 3041/4885NR1H4 3843/4885HDAC3 2555/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | EPHX2 3041/4885NR1H4 3843/4885HDAC3 2555/4885 |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | LPO, MPO, CAT | EPHX2 3007/4885NR1H4 3803/4885HDAC3 2558/4885 |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | EPHX2 3007/4885NR1H4 3803/4885HDAC3 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.